Modern approaches to the treatment of inoperable non-small cell lung cancer

Summary. Non-small cell lung cancer сontinues to hold the first place in the structure of oncologic morbidity and mortality. Traditional chemotherapy does not provide long-term benefit for patients with metastatic non-small cell lung cancer. Patients with driver mutations demonstrate better response rate only in 25–30% cases. Thus, working out the new treatment schemes using principally new modus operandi of medicines is actual for patients with lung cancer. Significant progress has been due to the immersed studying of relations of the immune system with tumor through the immune checkpoints´ (PD-1 receptor and PD-L1 ligand) system.